Curis (CRIS)
(Real Time Quote from BATS)
$5.26 USD
-0.11 (-2.05%)
Updated Sep 25, 2024 10:46 AM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 1 - 20 ( 305 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q24 Results; TakeAim Lymphoma and Leukemia Data Expected at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Results; TakeAim Leukemia Top Line Data Expected Next Week
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Multiple Updates For Emavusertib Anticipated in 2024; Lowering PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Investigator-Initiated Clinical Trial Agreement FKeytruda in Metastatic Melanoma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for CRIS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Lymphoma Data At ASH; Frontline AML Triplet Combination Phase 1 Trial to Initiate in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; TakeAim Leukemia and TakeAim Lymphoma Updates Expected in 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study of Emavusertib in AML/MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; Plans for FDA Meeting in 3Q23 to Discuss New TakeAim Leukemia Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q22 Results; Required Patients at 200mg Dose of Emavusertib Have Been Enrolled; FDA Meeting Expected 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Expectations for Positive Updated
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Highlights From the Second Annual VISTA Symposium
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
FDA Allows Resumption of Enrollment in Monotherapy Dose Escalation Phase of the TakeAim Leukemia Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Still Awaiting the Clinical Holds to Lift
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E